Inhibitors in haemophilia: pathophysiology.

Abstract excerpt

Development of inhibitors to coagulation factors is one of the major problems faced by people with haemophilia. Up to a third of patients, following treatment with factor concentrates, will develop an antibody (inhibitor) to that factor, rendering it inactive, and leaving the patient at risk from life-threatening bleeding. Evidence shows that this immune response is T-cell-dependent, but as yet, the epitopes...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies
• Share to B-Lymphocytes
• Share to Cloning, Molecular